für Strahlentherapie Eckert & Ziegler: New Contract for Radiation Therapy

Last Updated: 30. Januar 2024By

I reported on German radiation and medical technology specialist Eckert & Ziegler (E&Z) just two weeks ago at this point. At the time, E&Z had announced an exciting collaboration with US biotech company ARTBIO.

Now, E&Z has announced another supply contract for radiopharmaceuticals, which I will go into detail about shortly. As a result, E&Z’s stock has once again increased and is already up nearly 17% since the beginning of the year. But first, let’s take a look at E&Z’s business model:

Eckert & Ziegler: The radiation and medical technology specialists Eckert & Ziegler is one of the world’s largest manufacturers of radioactive components for medical, scientific, and measurement purposes. The company mainly focuses on the development of radiation technologies for use as cancer and heart treatments, as well as for nuclear medical imaging.

The main customers are international medical device manufacturers and clinics. On behalf of medical device manufacturers, the group takes on the development, testing, production, and market launch of new, weakly radioactive products.

In addition to medical components, Eckert & Ziegler AG also offers radioactive radiation sources for use in specialized measuring devices or for scientific applications worldwide.

New supply contract for radiopharmaceuticals Eckert & Ziegler and Full-Life Technologies, a globally operating radiotherapeutics company, have signed a contract for the supply of Actinium-225 (Ac-225). The agreement gives Full-Life access to Eckert & Ziegler’s high-purity Actinium-225, a radionuclide for the development of the next generation of therapeutic radiopharmaceuticals.

Ac-225 has proven to be a promising drug for the treatment of cancer. The radioisotope releases highly effective alpha particles with high energy and short penetration depth, enabling precise targeting of tumor cells, including hard-to-reach micrometastases. At the same time, the impact on surrounding healthy tissue is minimized. Due to its potential, experts from research and industry expect a significant increase in demand for Ac-225 in the coming decade.

E&Z CEO Harald Hasselmann comments on the supply contract as follows: „We are pleased to have entered into a supply cooperation with Full-Life Technologies, making it easier for them to enter clinical development.“

In my opinion, this supply contract makes E&Z’s stock even more attractive! You can find out more about E&Z in my stock service „The Portfolio Optimizer“. The stock made it onto my selection list „Small Cap Favorites 2024“ in December.